Vyant Bio, Inc. VYNT
0.19 USD 0.00 (+0.00%)
Dec 29, 2023, 3:39 PM EST
0.175 Day range 0.20
0.141 52-week range 1.58
News
globenewswire.com Vyant Bio Provides Update on Winddown Activities CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its…
globenewswire.com Vyant Bio Provides Update on Winddown Activities CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its…
globenewswire.com Vyant Bio Announces Stockholder Approval of Plan of Dissolution CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the…
globenewswire.com Vyant Bio Announces Completion of StemoniX Asset Sale CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the…
globenewswire.com Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special…
globenewswire.com Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the…
globenewswire.com Vyant Bio Announces Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the…
globenewswire.com Vyant Bio Announces Adjournment of Special Meeting of Stockholders CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the…
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets —Combines Three Leading Human Biomimetic Organoid Platform Technologies for Neurological Drug Discovery— —AxoSim Gains microBrain™ Intellectual Property from StemoniX, Along With Expert Scientific…
proactiveinvestors.com Vyant Bio to pursue listing on OTC Pink Open Market Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist from the exchange.
investorplace.com Why Is Vyant Bio (VYNT) Stock Down 35% Today? Vyant Bio (NASDAQ: VYNT ) stock is taking a beating on Tuesday after the biotechnology company announced plans to delist its shares. According to a press release, the company's Board of Directors…
proactiveinvestors.com Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agreed in principle to step down from their respective…
proactiveinvestors.ca Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value. The biotechnology…
seekingalpha.com Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Dr.…
proactiveinvestors.ca Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at least the end of 2023. The company had $9.4 million…
proactiveinvestors.com Vyant Bio showcases 'promise and potential' of its drug discovery platform at Boston medical conference Vyant Bio (NASDAQ:VYNT) Inc senior scientist Matthew Green delivered poster presentations this week at the Loulou Foundation's CDKL5 forum held in Boston. CDKL5 (cyclin-dependent kinase-like 5)…
proactiveinvestors.ca Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, allowing Reaction to expand its suite of drug…
globenewswire.com Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022 - To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases
globenewswire.com Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex…
proactiveinvestors.com Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early next year based on pre-clinical efficacy data and…